Santen Pharmaceutical Co Ltd (JP:4536)
:4536
Want to see JP:4536 full AI Analyst Report?
Top Page
Santen Pharmaceutical Co
(4536)
Select Model
Select Model
Rating:71Outperform
Price Target:
¥2,006.00
▲(25.61% Upside)
Action:Upgraded
Date:05/14/26
Overall score is supported primarily by strong financial positioning (low leverage and solid recent profitability) and reasonable valuation (P/E ~15.7 with a ~2.09% yield). The main drag is weak technical momentum, with oversold readings (RSI ~28.5, Stoch ~9.3) and a negative MACD indicating near-term pressure.
Positive Factors
Conservative balance sheet
Zero reported debt in 2026 and a sizable equity base provide durable financial flexibility. This reduces refinancing and solvency risk, supports sustained R&D and commercialization investment, and gives capacity for opportunistic M&A or shareholder returns during cyclical stress.
Negative Factors
Earnings volatility
Historical swings including a 2023 net loss show earnings can be inconsistent, complicating long-range planning. Volatility undermines predictability of free cash flow and returns on equity, making it harder to reliably fund R&D, dividends, or large strategic initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Zero reported debt in 2026 and a sizable equity base provide durable financial flexibility. This reduces refinancing and solvency risk, supports sustained R&D and commercialization investment, and gives capacity for opportunistic M&A or shareholder returns during cyclical stress.
Read all positive factors
Santen Pharmaceutical Co (4536) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥612.35B
Dividend Yield2.3%
Average Volume (3M)1.30M
Price to Earnings (P/E)15.7
Beta (1Y)0.45
Revenue Growth-2.79%
EPS Growth9.69%
CountryJP
Employees3,744
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)114.03
Shares Outstanding322,290,160
10 Day Avg. Volume1,416,570
30 Day Avg. Volume1,302,203
Financial Highlights & Ratios
PEG Ratio1.62
Price to Book (P/B)1.97
Price to Sales (P/S)2.01
P/FCF Ratio15.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)113.01
Revenue Forecast (FY)¥299.52B
Santen Pharmaceutical Co Business Overview & Revenue Model
Company Description
Santen Pharmaceutical Co., Ltd. (Ticker: 4536) is a global pharmaceutical company headquartered in Japan, specializing in the research, development, manufacturing, and marketing of products primarily for ophthalmology. Established in 1890, Santen ...
How the Company Makes Money
Santen primarily makes money by selling ophthalmic pharmaceutical products. Revenue is mainly generated from (1) prescription eye-drop and other ophthalmology drug sales to healthcare channels (e.g., through wholesalers/distributors and pharmacies...
Santen Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
88
Very Positive
Cash Flow
70
Positive
| Breakdown | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 291.62B | 300.00B | 301.96B | 279.04B | 266.26B |
| Gross Profit | 160.97B | 163.21B | 163.88B | 156.57B | 146.85B |
| EBITDA | 63.57B | 74.18B | 70.08B | 49.26B | 53.03B |
| Net Income | 37.37B | 36.26B | 26.64B | -14.95B | 27.22B |
Balance Sheet | |||||
| Total Assets | 423.03B | 409.28B | 435.70B | 421.18B | 459.98B |
| Cash, Cash Equivalents and Short-Term Investments | 80.88B | 93.00B | 94.58B | 57.90B | 83.01B |
| Total Debt | 0.00 | 33.95B | 35.16B | 35.96B | 22.00B |
| Total Liabilities | 127.02B | 124.10B | 130.33B | 127.88B | 123.13B |
| Stockholders Equity | 296.99B | 286.24B | 306.05B | 293.98B | 337.49B |
Cash Flow | |||||
| Free Cash Flow | 36.66B | 54.27B | 63.33B | 19.87B | 28.70B |
| Operating Cash Flow | 43.50B | 60.93B | 72.65B | 37.15B | 46.04B |
| Investing Cash Flow | -12.97B | -8.22B | -6.14B | -26.78B | -35.17B |
| Financing Cash Flow | -49.35B | -53.31B | -34.03B | -37.22B | 5.56B |
Santen Pharmaceutical Co Technical Analysis
Positive
1597.00
Price Trends
1732.77
Positive
1709.22
Positive
1635.65
Positive
Market Momentum
33.22
Negative
65.12
Neutral
87.50
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4536, the sentiment is Positive. The current price of 1597 is below the 20-day moving average (MA) of 1722.30, below the 50-day MA of 1732.77, and below the 200-day MA of 1635.65, indicating a bullish trend. The MACD of 33.22 indicates Negative momentum. The RSI at 65.12 is Neutral, neither overbought nor oversold. The STOCH value of 87.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4536.
Santen Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥52.64B | 10.70 | ― | 3.22% | 11.84% | -5.68% | |
71 Outperform | ¥612.35B | 15.65 | 10.89% | 2.30% | -2.79% | 9.69% | |
67 Neutral | ¥4.13T | 25.93 | 7.97% | 3.61% | 11.87% | 474.27% | |
54 Neutral | ¥124.63B | 21.53 | 7.81% | 1.78% | 3.39% | 7.21% | |
54 Neutral | ¥281.59B | 18.74 | 4.38% | 2.03% | 2.47% | 164.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | ¥6.84B | -9.94 | ― | ― | -85.26% | -468.26% |
* Healthcare Sector Average
JP:4536
Santen Pharmaceutical Co
1,883.00
336.50
21.76%
JP:4503
Astellas Pharma
2,278.00
940.78
70.35%
JP:7780
Menicon Co
1,682.00
632.75
60.30%
JP:8086
Nipro
1,713.50
478.32
38.72%
JP:4890
Tsubota Laboratory Incorporated
259.00
-127.00
-32.90%
JP:5889
Japan Eyewear Holdings Co.,Ltd.
2,177.00
38.83
1.82%
Santen Pharmaceutical Co Corporate Events
Santen Pharmaceutical Lifts Earnings and Dividends, Signals Growth for FY2027
May 12, 2026
Santen Pharmaceutical reported a slight decline in revenue for the year ended March 31, 2026, but achieved growth in operating profit, net profit, and earnings per share, alongside improved profitability ratios and a stronger equity base. Cash flo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.